From our own synthesis of the trial findings, we propose the following steps, as shown in Figure 2: firstly, lifestyle recommendation and the addition of metformin should remain the first step and the backbone of management of T2D; secondly, one needs to assess for cardiac risk; in case heart failure is present, then SGLT2i is added preferentially after metformin, followed by GLP-1 RA. Here, GLP1R is linked to type 2 diabetes mellitus.